Hubbry Logo
Prostaglandin E2Prostaglandin E2Main
Open search
Prostaglandin E2
Community hub
Prostaglandin E2
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Prostaglandin E2
Prostaglandin E2
Prostaglandin E2
View on Wikipedia
from Wikipedia

Prostaglandin E2
Clinical data
Trade namesProstin E2, Cervidil, Propess, others
Other namesPGE2, (5Z,11α,13E,15S)-11,15-Dihydroxy-9-oxo-prosta-5,13-dien-1-oic acid
AHFS/Drugs.comMonograph
MedlinePlusa682512
License data
Pregnancy
category
Routes of
administration		Intravaginal, IV
ATC code
Legal status
Legal status
Identifiers
  • (5Z,11α,13E,15S)-7-[3-hydroxy-2-(3-hydroxyoct-1-enyl)- 5-oxo-cyclopentyl] hept-5-enoic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.006.052 Edit this at Wikidata
Chemical and physical data
FormulaC20H32O5
Molar mass352.471 g·mol−1
3D model (JSmol)
  • CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1C/C=C\CCCC(=O)O)O)O
  • InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-17,19,21,23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,19+/m0/s1 ☒N
  • Key:XEYBRNLFEZDVAW-ARSRFYASSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Prostaglandin E2 (PGE2), also known as dinoprostone, is a naturally occurring prostaglandin with oxytocic properties that is used as a medication.[2][3][4] Dinoprostone is used in labor induction, bleeding after delivery, termination of pregnancy, and in newborn babies to keep the ductus arteriosus open.[2][5] In babies it is used in those with congenital heart defects until surgery can be carried out.[5] It is also used to manage gestational trophoblastic disease.[4] It may be used within the vagina or by injection into a vein.[2][6]

PGE2 synthesis within the body begins with the activation of arachidonic acid (AA) by the enzyme phospholipase A2. Once activated, AA is oxygenated by cyclooxygenase (COX) enzymes to form prostaglandin endoperoxides. Specifically, prostaglandin G2 (PGG2) is modified by the peroxidase moiety of the COX enzyme to produce prostaglandin H2 (PGH2) which is then converted to PGE2.[7][8]

Common side effects of PGE2 include nausea, vomiting, diarrhea, fever, and excessive uterine contraction.[2] In babies there may be decreased breathing and low blood pressure.[5] Caution should be taken in people with asthma or glaucoma and it is not recommended in those who have had a prior C-section.[9] It works by binding and activating the prostaglandin E2 receptor which results in the opening and softening of the cervix and dilation of blood vessels.[2][5]

Prostaglandin E2 was first synthesized in 1970 and approved for medical use by the FDA in the United States in 1977.[5][2] It is on the World Health Organization's List of Essential Medicines.[10] Prostaglandin E2 works as well as prostaglandin E1 in babies.[5]

Physiological effects

[edit]

Dinoprostone has important effects in labor by inducing softening of the cervix and causing uterine contraction, and also stimulates osteoblasts to release factors that stimulate bone resorption by osteoclasts.[11]

Natural prostaglandins, including PGE1 and PGE2, are important in the structure and function of the ductus arteriosus in fetuses and newborns.[12] They allow the ductus arteriosus to remain open, providing the necessary connection between the pulmonary artery and descending aorta that allows the blood to bypass the fetus's underdeveloped lungs and be transported to the placenta for oxygenation.[12] The ductus arteriosus normally begins to close upon birth due to an increase of PGE2 metabolism, but in newborns with congenital heart disease, prostaglandins can be used to keep the ductus arteriosus open longer than normal to sustain healthy oxygen saturation levels in the blood.[7][12] Although PGE1 is more commonly used in this setting, there has been a report of oral PGE2 being used to treat ductus-dependent congenital heart diseases in newborns to delay surgical treatment until the pulmonary arteries grew.[13] In addition, PGE2 was used in another report to dilate the ductus arteriosus in newborns with various cardiovascular defects to allow for better perfusion of the lungs and kidneys.[14] On the other hand, the post-partal synthesis of PGE2 in newborns is considered one cause of patent ductus arteriosus.[15]

When administered in aerosol form, PGE2 serves as a bronchodilator, but its use in this setting is limited by the fact that it also causes coughing.[7]

PGE2, similarly to PGE1, acts as a direct vasodilator by acting on smooth muscle to cause dilation of blood vessels.[7] In addition, PGE2 inhibits platelet aggregation.[7]

PGE2 also suppresses T cell receptor signaling and proliferation, and may play a role in resolution of inflammation.[7][16] In addition, PGE2 limits the immune response by preventing B-lymphocyte differentiation and their ability to present antigens.[7]

Central and peripheral nervous systems effects

[edit]

Prostaglandin E2 (PGE2) has a variety of functions within the central nervous system and peripheral nervous system. When PGE2 interacts with EP3 receptors, it increases body temperature, resulting in fever.[17][18] PGE2 is also a predominant prostanoid that contributes to inflammation via enhancing edema and leukocyte infiltration from increased vascular permeability (allowing more blood flow into an inflamed area of the body) when acting on EP2 receptors. The use of nonsteroidal anti-inflammatory drugs (NSAIDs) blocks the activity of COX-2, resulting in a decrease of PGE2 production. NSAIDs blocking COX-2 and decreasing the production of PGE2 remediates fever and inflammation.[7][19]

Additionally, PGE2 acting on EP1 and EP4 receptors are a component in feeling pain via inflammatory nociception.[20] When PGE2 binds to EP1 and EP4 receptors, an increase in excitability via cation channels as well as inhibition of hyperpolarizing potassium (K+) channels, increase membrane excitability. As a result, this causes peripheral nerve endings to report painful stimuli.[7]

Immunity

[edit]

As mentioned previously, prostaglandin E2 (PGE2) contributes to the inflammation when bound to EP2 receptors. In terms of immunity, prostaglandins have the ability to regulate lymphocyte function. PGE2 affects T-lymphocyte formation by regulating apoptosis of immature thymocytes. In addition, it can suppress an immune response by inhibiting B lymphocytes from forming into antibody-secreting plasma cells. When this process is suppressed, it causes a decrease in a humoral antibody response because of the decrease in production of antibodies. PGE2 also has roles in inhibition of cytotoxic T-cell function, cell division of T-lymphocytes, and the development of TH1 lymphocytes.[7][21]

Neurological effects

[edit]

In response to physiologic and psychologic stress, prostaglandin E2 (PGE2) is involved in several inflammation and immunity pathways. As one of the most abundant prostaglandins in the body, PGE2 is involved almost all typical inflammation markers such as redness, swelling, and pain.[22] It regulates these responses through binding to G coupled protein prostaglandin E2 receptors (EP1, EP2, EP3, and EP4). The activation of these different EP receptors is dependent on the type of triggering stress stimuli and results in the corresponding stress response. Activation of EP1 via PGE2 results in the suppression of impulse behaviors in response to psychological stress. PGE2 is involved in regulating illness-induced memory impairment via activation of EP2. PGE2 activation of EP3 results in regulation of illness induced fever.[17][23][18] EP4 is functionally similar to EP2 and has also been shown in studies to have a role in hypothermia and anorexia.[24] In addition to inflammatory effects, PGE2 has been shown to have anti-inflammatory effects as well, due to its different actions on varying receptors.[22]

Smooth muscle effects

[edit]

Prostaglandin E2 (PGE2) serves a significant role in vascular smooth muscle tone regulation. It is a vasodilator produced by endothelial cells. It promotes vasodilation of smooth muscles by increasing the activity of cyclic adenosine monophosphate (cAMP) to decrease intracellular calcium levels via the IP and EP4 receptors.[7] Conversely, PGE2 can also induce vasoconstriction via activation of EP1 and EP3 receptors, which activates the Ca2+ pathway and decreased cAMP activity.[25]

Within the gastrointestinal tract, PGE2 activates smooth muscles to cause contractions on longitudinal muscle when acting on EP3 receptors. In contrast, PGE2 effects on respiratory smooth muscle result in relaxation.[26]

Kidney effects

[edit]

Prostaglandin E2 (PGE2), along with other prostaglandins, are synthesized within the cortex and medulla of the kidney. The role of renal COX-2-derived PGE2 within the kidney is to maintain renal blood flow and glomerular filtration rate (GFR) through localized vasodilation. COX-2-derived prostanoids work to increase medullary blood flow as well as inhibit sodium reabsorption within kidney tubules. PGE2 also assists the kidneys with systemic blood pressure control by modifying water and sodium excretion. In addition, it is also thought to activate EP4 or EP2 to increase renin release, resulting in an elevation of GFR and sodium retention to raise systemic blood pressure levels within the body.[7]

Medical uses

[edit]

Cervical ripening

[edit]

In the setting of labor and delivery, cervical ripening (also known as cervical effacement) is a natural process that occurs before labor, in which the cervix becomes softer, thinner, and dilated, enabling the fetus to pass through the cervix.[3] A ripe cervix is favorable prior to induction of labor, which is a common obstetric practice, and increases the chances for a successful induction.[27] Pharmacological methods are sometimes required to induce cervical ripening that does not occur naturally.[28] The natural ripening of the cervix is mediated by prostaglandins, thus a common pharmacological method is to use external prostaglandins such as PGE2, or dinoprostone.[3] Results of a systematic review and meta-analysis of the literature found that outpatient cervical ripening with dinoprostone or single-balloon catheters did not increase the risk of cesarean deliveries.[29][30]

Prostaglandin E2 (PGE2) achieves cervical ripening and softening by stimulating uterine contractions as well as directly acting on the collagenase present in the cervix to soften it.[7] There are currently two formulations of PGE2 analog available for use in cervical ripening: Prepidil, a vaginal gel, and Cervidil, a vaginal insert.[27] PGE2 is similar to oxytocin in terms of successful labor induction and the time from induction to delivery.[7]

Termination of intrauterine pregnancy

[edit]

PGE2 is a common pharmacological method of termination of pregnancy, particularly in the second trimester or for missed abortion, which is a miscarriage in which the fetus did not evacuate the uterus.[7][31][32] However, PGE2 is not feticidal, and only induces abortion by stimulating uterine contractions.[4] It is recommended that 20 mg of dinoprostone vaginal suppository be administered every three to five hours to evacuate the uterus.[7][4] The abortion should occur within 24 hours after the beginning of administration of dinoprostone; if it does not, dinoprostone should no longer be given and other interventions would be required, such as dilation and curettage.[7][4]

Side effects

[edit]

A common side effect of prostaglandin E2 is its effect on gastrointestinal smooth muscle resulting in nausea, vomiting and diarrhea. Other side effects include headache, shivering, and chills.[4] The suppository form of prostaglandin E2 is associated with increased severity of these symptoms. Fever is also a common side effect with use of prostaglandin E2. Administration of prostaglandin E2 should be stopped if a person experiences side effects such as fever.[4]

The insert and gel forms have been shown to have minimal gastrointestinal effects, but are more associated with increase stimulation of the uterus as well as fetal distress.[4] Uterine hyperstimulation is effectively treated by stopping use of prostaglandin E2.[4] Other monitoring parameters include sustained uterine contractions and fetal distress.[4] In babies there may be decreased breathing and low blood pressure.[5] Care should be taken in people with asthma or glaucoma and it is not recommended in those who have had a prior C-section.[9]

Mechanism of action

[edit]

Prostaglandin E2 (PGE2) binds to G protein-coupled receptors (GPCRs) EP1, EP2, EP3, and EP4 to cause various downstream effects to cause direct contractions in the myometrium.[4] In addition, PGE2 inhibits Na+ absorption within the Thick Ascending Limb (TAL) of the Loop of Henle and ADH-mediated water transport in collecting tubules. As a result, blockage of PGE2 synthesis with NSAIDs can limit the efficacy of loop diuretics.[4]

Administration

[edit]

Prostaglandin E2 (PGE2) should only be administered by, or under the direct supervision of, a physician and careful monitoring should be performed.[4] PGE2 comes in many dosage forms with varying pharmacokinetic properties. For example PGE2 can come in a gel formulation that requires six hour dosing or it can come as a slow release dinoprostone pessary that does not need to be re-administered and can be taken out if necessary.[33] In a quality improvement project done in UK, the switch from prostaglandin gel to the slow release dinoprostone pessary was able to lower cesarian section rates in women undergoing induction of labor in maternity care.[33]

For the vaginal insert (brand name Cervidil), the manufacturer recommends keeping the medication frozen until use since it does not need to be warmed to room temperature.[34] Once the package is open, a water miscible lubricant may be used to insert the medication, using your finger place the device into the vagina and position the device transversely in the posterior vaginal fornix.[34] The person receiving the drug should remain laying down for two hours after administration of the insert is complete.[34] The manufacturer also recommends waiting 30 minutes after removal of insert before starting oxytocin.[34]

The vaginal gel (brand name Prostin E2, Canada) is administered through a prefilled syringe and the medication is placed in the posterior fornix of the vagina. After administration people should stay laying down for at least 30 minutes after they have received the drug.[35]

Contraindications

[edit]

Contraindications to a medication are any reasons to not use the drug. Prostaglandin E2 (PGE2) is used to induce labor and should not be used in people that are contraindicated to give birth vaginally or spontaneous labor.[28] PGE2 should not be used in people with allergies to prostaglandins or any components in the drugs formulations.[4] PGE2 should be stopped before other oxytocic agents like oxytocin are given.[4]

Dinoprostone as a vaginal suppository is contraindicated for women with acute pelvic inflammatory disease or active disease of the cardiovascular, respiratory, hepatic, or renal systems. Caution is required for people with a history of cervical malignancy, hypo- or hypertension, anemia, epilepsy, jaundice, asthma, or pulmonary diseases. The suppository formulation is also not indicated for viable fetus evacuation.[4]

Endocervical gel is contraindicated in those with who have a history of C-sections or major uterine surgery, if the fetus is in distress and delivery is not imminent, vaginal bleeding throughout the pregnancy that is unexplained, history of difficult labors and deliveries, have cephalopelvic disproportion, less than six previous term babies with nonvertex presentation, hyper or hypotonic uterine patterns.[4]

Toxicity

[edit]

When prostaglandin E2 (PGE2) is given in excess, hyper-stimulation of the uterus occurs and immediate discontinuation of the drug usually results in resolution of toxic effects.[36][4] If symptoms continue a beta adrenergic drug (e.g. terbutaline) can be used.[citation needed]

There are many different dosage forms of PGE2. The pharmacokinetic properties vary between dosage forms and should not be interchanged. A medication error was cited in the Institute for Safe Medication Practices where Prostin E2 was used in place of Cervidil. The hospital had run out of Cervidil which is a 10 mg endocervical insert and the provider decided to use half of a 20 mg Prostin E2 vaginal suppository. Cervidil delivers the drug at a constant rate and can be removed as necessary while Prostin E2 dissolves immediately and can not be removed. This error resulted in an emergency C-section since the fetus's heart rate dropped suddenly.[37]

Pharmacokinetics

[edit]

The synthetic PGE2 dinoprostone has a plasma half-life of approximately 2.5–5 minutes, after vaginal administration, with most metabolites being excreted in the urine.[7]

History

[edit]

Swedish physiologist Ulf von Euler and British physiologist M.W. Goldblatt, first discovered prostaglandins independently in 1935 as factors contained in human seminal fluid.[38] Prostaglandins were noted for having blood pressure reducing effects and smooth muscle regulation effects.[39] Prostaglandin E2 itself was identified in 1962 by Swedish biochemist Sune Bergström in the seminal fluid of sheep.[38] The structure of prostaglandins is conserved in mammals, but it is also produced by marine organisms which allowed for more research into their biological roles.[39] Prostaglandins were discovered to be products of arachidonic acid and with the ability to radio label arachidonic acid in the early 1960s, American chemist E.J. Corey was able to synthesize prostaglandin E2 in the lab in the 1970.[39] This advancement paved the way for later studies that helped define the actions and response of prostaglandin E2. Prostaglandin E2 was approved for medical use in the United States in 1977 and it is on the World Health Organization's List of Essential Medicines.[2][10] Prostaglandin E2 was approved by the FDA in 1977.[40]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Prostaglandin E2

View on Grokipedia
from Grokipedia

(PGE₂) is a bioactive lipid mediator synthesized from via sequential actions of enzymes and prostaglandin E synthases, such as microsomal PGE synthase-1. PGE₂ exerts its effects primarily through binding to four distinct G-protein-coupled receptors (EP1–EP4), enabling potent regulation of cellular processes at nanomolar concentrations. As a central player in the inflammatory cascade, PGE₂ promotes , enhances , and sensitizes nociceptors to amplify signaling, while also serving as the primary pyretic mediator in the to elevate body temperature during fever. Beyond acute responses, PGE₂ modulates adaptive immunity by suppressing T-cell proliferation and production, influences gastrointestinal mucosal integrity, and facilitates cervical ripening essential for parturition. Dysregulated PGE₂ biosynthesis underlies numerous pathologies, including chronic inflammatory diseases, progression via promotion of and tumor cell survival, and impaired tissue repair; these roles have positioned COX inhibitors and emerging EP receptor antagonists as therapeutic targets, though challenges persist in balancing beneficial homeostatic functions against pathological overproduction.

Biosynthesis and Chemical Properties

Enzymatic Synthesis Pathway

The biosynthesis of prostaglandin E2 (PGE2) begins with the release of from phospholipids, primarily catalyzed by A2 (PLA2) enzymes, which hydrolyze the sn-2 ester bond of glycerophospholipids. Arachidonic acid, a 20-carbon polyunsaturated (C20:4 n-6), is then metabolized to the unstable endoperoxide intermediate prostaglandin H2 (PGH2) in a two-step reaction involving cyclooxygenation and peroxidation, mediated by (COX) enzymes. These bifunctional enzymes exist as two main isoforms: COX-1, which is constitutively expressed and maintains baseline levels, and COX-2, which is inducible by inflammatory stimuli such as cytokines and growth factors, leading to upregulated PGE2 production during . PGH2, the committed precursor for multiple prostanoids, is selectively converted to PGE2 by terminal E synthases (PGES), a family of glutathione-dependent or independent isomerases. The primary isoforms include cytosolic PGES (cPGES/p23), which is constitutive and couples mainly with COX-1 for housekeeping functions; microsomal PGES-1 (mPGES-1), an inducible enzyme often functionally coupled with COX-2 in perinuclear/ membranes to drive inflammation-associated PGE2 synthesis; and microsomal PGES-2 (mPGES-2), which is constitutive and Golgi-associated but less specific. This terminal involves the glutathione-mediated reduction of PGH2's endoperoxide bond, yielding the enone structure of PGE2. The pathway's efficiency is enhanced by spatial and functional coupling of , particularly COX-2 and mPGES-1 in lipid bodies or , minimizing PGH2 leakage to alternative synthases. Regulatory factors, including substrate availability, induction (e.g., via for COX-2 and mPGES-1), and inhibitors like NSAIDs targeting COX, modulate flux through this pathway.

Molecular Structure and Stability

Prostaglandin E2 (PGE2) possesses the molecular formula C20H32O5 and a molecular weight of 352.47 g/mol. Its systematic IUPAC name is (5Z,11α,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dienoic acid. The core structure comprises a ring substituted at C-9 with a group and at C-11 with an α-hydroxy group, connected to two side chains: an ω-chain featuring a trans double bond between C-13 and C-14 and a hydroxyl at C-15 (S configuration), and an α-chain with a cis double bond between C-5 and C-6 terminating in a . This configuration distinguishes PGE2 from other prostaglandins, such as PGE1, which lacks the C-5 double bond. PGE2 exhibits pH-dependent chemical stability, with degradation primarily occurring via in neutral to alkaline aqueous environments. At physiological (around 7.4), it undergoes non-enzymatic to A2 (PGA2), involving elimination of from the C-9 and C-11 hydroxy groups to form a cyclopentenone ring, following first-order kinetics accelerated by temperatures above 37°C. In contrast, acidic conditions ( 2.6–4.0) enhance stability, yielding half-lives of approximately 300 hours at 25°C, though extreme acidity ( <2) or alkalinity ( >10) shortens this to under 50 hours due to alternative or pathways. In non-aqueous media, PGE2 demonstrates superior stability; as a lyophilized or , it remains viable for at least one year when stored desiccated at -20°C. Solutions in (1–10 mg/mL) at 4°C retain over 90% potency for 24–36 months, while DMSO or stocks at -20°C support long-term storage with minimal loss. These properties necessitate careful handling, such as avoiding prolonged exposure to aqueous buffers at neutral and preferring organic solvents for dilutions, to prevent autodegradation during experimental or pharmaceutical applications.

Receptors and Molecular Mechanisms

EP Receptor Subtypes and Distribution

The EP receptors for prostaglandin E2 consist of four distinct subtypes—EP1, , EP3, and EP4—each encoded by separate genes and characterized by specific G-protein coupling preferences that dictate their signaling profiles. These subtypes mediate diverse physiological responses through differential expression across tissues, with EP3 and EP4 showing the broadest distribution in mammalian systems, including humans. EP1 receptors primarily couple to proteins, leading to activation, production, and elevated intracellular calcium levels. Their expression is more restricted, with prominent localization in renal tissues, , smooth muscle, (), pulmonary veins, colon, , and cerebral parenchymal arterioles in humans. EP1 distribution supports roles in smooth muscle contraction and water reabsorption. EP2 receptors couple to Gs proteins, stimulating adenylate cyclase to increase cyclic AMP levels and activate protein kinase A. They are expressed in leukocytes, macrophages, lung, spleen, thymus, vascular smooth muscle, and epidermal layers (basal and spinous) in human skin. This subtype's presence in immune and airway tissues aligns with functions in vasodilation and immune modulation. EP3 receptors couple to proteins, inhibiting adenylate cyclase and reducing cyclic AMP, with multiple splice variants influencing isoform-specific signaling. They exhibit near-ubiquitous expression across human tissues, including , , , renal vasculature, (particularly and basal layers), and . High levels in neural and epithelial sites underscore involvement in and . EP4 receptors, like EP2, couple to Gs proteins to elevate cyclic AMP, but also engage β-arrestin pathways for PI3K/Akt activation. They are widely distributed in heart, lung, kidney, bone, vascular smooth muscle, endothelial cells, colon, and epidermal keratinocytes, with upregulation noted in certain human skin cancers like squamous cell carcinoma. This broad profile facilitates roles in inflammation resolution, bone homeostasis, and cardiovascular function.
SubtypeG-Protein CouplingKey Tissues in Humans
EP1, , GI tract, , , cerebral arterioles
EP2Gs, , , leukocytes, epidermis
EP3Gi, , GI tract, , nearly ubiquitous
EP4GsHeart, , , , vascular , colon,

Intracellular Signaling Pathways

Prostaglandin E2 (PGE2) primarily transduces signals through four G protein-coupled receptors (EP1–EP4), each coupling to specific heterotrimeric G proteins to activate distinct intracellular cascades that regulate cellular functions such as proliferation, migration, and inflammation. These pathways involve second messengers like calcium ions, cyclic AMP (cAMP), and protein kinases, with outcomes varying by receptor subtype, tissue distribution, and context. The EP1 receptor couples to Gq proteins, stimulating (PLC) to hydrolyze (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers release of calcium from stores, elevating cytosolic Ca²⁺ levels, while DAG recruits and activates (PKC), which phosphorylates downstream targets to mediate effects like contraction and . The receptor couples to Gs proteins, activating adenylate cyclase to elevate cAMP levels, which binds and activates (PKA); this phosphorylates cAMP response element-binding protein (CREB) and other effectors to promote gene transcription. EP2 induces a sustained response, particularly at higher PGE2 concentrations (≥1 µM), and can engage phosphatidylinositol 3-kinase (PI3K)/Akt signaling via β-arrestin-mediated pathways or epidermal growth factor receptor (EGFR) transactivation, independent of cAMP in some contexts. integrity is required for efficient EP2 signaling. The EP3 receptor, with multiple isoforms, predominantly couples to Gi proteins, inhibiting adenylate cyclase and reducing cAMP production, thereby counteracting Gs-mediated effects and influencing processes like aggregation and . Some isoforms may weakly couple to Gs or other pathways, but Gi-mediated cAMP inhibition remains the primary mechanism. The EP4 receptor also couples to Gs, increasing cAMP via adenylate cyclase activation and subsequent PKA/CREB signaling, but produces a transient peak (peaking ~40 seconds post-stimulation) that subsides due to receptor internalization; it additionally recruits for PI3K activation at low PGE2 doses (e.g., 0.1 µM) and engages β-arrestin/EGFR routes for Akt phosphorylation. Crosstalk between EP2 and EP4 can attenuate cAMP via Gαs competition during co-activation. These receptor-specific pathways enable PGE2 to elicit context-dependent responses, with Gs-coupled receptors (/EP4) often promoting relaxation and , Gq/EP1 driving excitation, and Gi/EP3 inhibiting adenylyl cyclase-dependent processes. Downstream convergence on effectors like RhoA or further diversifies outcomes in immunity and repair.

Physiological Functions

Reproductive and Uterine Effects

Prostaglandin E2 (PGE2) plays a central role in uterine contractility, primarily by binding to EP receptor subtypes in myometrial cells, which triggers intracellular signaling cascades leading to increased calcium influx and contraction strength. At higher concentrations, PGE2 induces robust suitable for , while lower doses may initially promote relaxation before shifting to contractile effects, reflecting a dose-dependent biphasic response. This mechanism has been exploited clinically since the , with PGE2 analogs like dinoprostone approved by the FDA for cervical ripening and in term pregnancies, reducing induction-delivery intervals and minimizing cesarean rates in favorable cases. In cervical ripening, PGE2 facilitates remodeling of the cervical by elevating inflammatory mediators such as cytokines and matrix metalloproteinases, which degrade and increase , thereby softening and dilating the to Bishop scores of 6 or higher in responsive patients. Intracervical or vaginal administration of PGE2 , typically at doses of 0.5–2 mg, achieves ripening in 70–90% of cases within 12–24 hours, outperforming in randomized trials and correlating with shorter labor durations compared to mechanical methods alone. However, risks include hyperstimulation in up to 5% of applications, necessitating fetal monitoring. Beyond labor, PGE2 contributes to mammalian female reproduction by promoting through elevated intrafollicular levels that drive cumulus- complex expansion via EP2 receptor activation and synthesis, culminating in follicle rupture and release. It also supports implantation and by modulating and vascularization at the maternal-fetal interface, with deficiencies in PGE2 synthesis linked to implantation failure in models. These effects underscore PGE2's indispensability in , though excessive levels may contribute to pathological conditions like preterm labor.

Cardiovascular and Renal Regulation

Prostaglandin E2 (PGE2) exerts complex effects on cardiovascular function primarily through its interaction with four EP receptor subtypes (EP1–EP4), which mediate both vasodilation and vasoconstriction depending on the subtype and context. Activation of EP2 and EP4 receptors promotes vascular relaxation via increased cyclic AMP (cAMP) levels, contributing to reduced vascular tone and hypotension, as demonstrated in studies where PGE2 infusion lowered blood pressure in wild-type mice through endothelium-dependent mechanisms involving nitric oxide synthase. Conversely, EP1 and EP3 receptors can induce vasoconstriction and elevate blood pressure; for instance, EP1 activation increases arteriolar tone in skeletal muscle, while central PGE2 signaling via these receptors has been linked to hypertension in animal models. EP3 antagonism has been shown to attenuate angiotensin II-induced hypertension by mitigating pressor responses. In the renal system, PGE2 is synthesized throughout the and plays a critical role in maintaining (GFR) and renal blood flow (RBF) by counteracting vasoconstrictive influences, such as those from angiotensin II or norepinephrine, particularly under conditions of reduced renal . It modulates tubular sodium and handling, primarily inhibiting in the medullary thick ascending limb and collecting duct via EP2 and EP4 receptors, which elevate cAMP and promote and . Intramedullary PGE2 infusion enhances urinary sodium excretion, supporting its role in salt balance during high dietary sodium intake. Disruption of PGE2 signaling, as seen with inhibitors, reduces sodium and excretion, underscoring its physiological necessity for renal . Elevated urinary PGE2 excretion correlates with increased risk of cardiovascular events and progression, potentially reflecting underlying inflammatory or hemodynamic dysregulation rather than direct . In pathological states like or renal , dysregulated PGE2 via specific EP receptors (e.g., EP1/EP3) may exacerbate fluid retention and vascular stiffness, while EP4 signaling offers protective .

Nervous System and Pain Modulation

Prostaglandin E2 (PGE2) serves as a key inflammatory mediator in the , primarily enhancing transmission by sensitizing peripheral nociceptors and amplifying central nociceptive processing in the spinal dorsal horn. Produced locally in response to tissue injury via (COX) enzymes acting on , PGE2 lowers the activation threshold of Aδ and C-fiber nociceptors, contributing to primary through peripheral and secondary via central mechanisms. This dual action facilitates the release of neuropeptides such as and (CGRP), exacerbating signaling during . In the peripheral nervous system, PGE2 binds to E-prostanoid (EP) receptors—predominantly EP1 and EP4—on neurons and sensory axons, triggering G-protein-coupled pathways that elevate cyclic AMP (cAMP) levels and activate (PKA). This leads to modulation of ion channels, including sensitization of transient receptor potential vanilloid 1 () and hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, thereby increasing neuronal excitability and responses to thermal and mechanical stimuli. A specific depolarizing mechanism involves EP4 receptor activation, which stimulates adenylate cyclase to raise cAMP, opening anoctamin-1 (ANO1) calcium-activated channels and causing efflux-dependent ; this in turn activates voltage-gated Nav1.8 to generate persistent action potentials, directly promoting spontaneous inflammatory without requiring synaptic input. Intracellular accumulation via the NKCC1 cotransporter sustains this process, with ANO1 blockade reducing PGE2-evoked by approximately 53%. Centrally, PGE2 acts on EP receptors (EP1–EP4) expressed in spinal nociceptive neurons that process input from both normal and inflamed tissues, inducing hyperexcitability akin to peripheral . EP2 receptors, in particular, inhibit α3 subunit-mediated inhibitory postsynaptic currents in dorsal horn neurons via PKA phosphorylation, resulting in spinal and enhanced transmission of nociceptive signals; genetic deletion of EP2 attenuates this inflammatory . EP1 contributes by elevating intracellular calcium through / pathways, while EP3 may amplify glutamate release, collectively shifting the balance toward pain during ongoing . These receptor-specific effects underscore PGE2's role in transitioning acute pain to chronic states, as observed in models of where central PGE2 levels correlate with sustained sensitization.

Immune System Interactions

Prostaglandin E2 (PGE2) is synthesized by immune cells such as macrophages and dendritic cells in response to inflammatory stimuli via the cyclooxygenase-2 (COX-2) pathway, acting primarily through four G-protein-coupled EP receptor subtypes (EP1–EP4) expressed on these cells. In innate immunity, PGE2 promotes acute inflammatory responses by enhancing vascular permeability, mast cell degranulation, and cytokine release from macrophages, yet it concurrently restrains excessive inflammation by inhibiting NLRP3 inflammasome activation and suppressing phagocytic activity in monocytes and macrophages. For instance, PGE2 limits macrophage maturation and polarizes them toward an M2-like anti-inflammatory phenotype, reducing pro-inflammatory cytokine production such as TNF-α while elevating IL-10. On dendritic cells (DCs), PGE2 exerts context-dependent effects: it can upregulate costimulatory molecules like OX40L, , and 4-1BBL to enhance T-cell priming in certain settings, but more commonly impairs DC maturation, migration, and , particularly in tumor microenvironments where it induces dysfunction via EP2/EP4 signaling and pathways involving IL-6/STAT3. This leads to reduced IFN-γ production and skewed immune responses favoring tolerance over activation. In adaptive immunity, PGE2 predominantly suppresses T-cell function by binding EP2/EP4 receptors on + and + T cells, inhibiting proliferation, secretion (e.g., IL-2, IFN-γ), and effector differentiation while promoting regulatory T-cell (Treg) expansion and Th2/Th17 imbalances that favor immune evasion. For example, in cancer, tumor-derived PGE2 restricts stem-like + T-cell expansion and induces exhaustion, contributing to impaired anti-tumor immunity. PGE2 also modulates B-cell responses indirectly through altered T-cell help, though direct effects remain less characterized. During inflammation resolution, facilitates a shift from pro-inflammatory to reparative phases by suppressing innate responses post-infection and generating myeloid-derived suppressor cells, but chronic elevation—often via COX-2 overexpression—perpetuates , exacerbating conditions like and tumorigenesis. This dual role underscores PGE2's context-specific actions, influenced by receptor subtype dominance and local concentrations, with EP4 often mediating suppressive effects in pathological states.

Gastrointestinal and Bone Homeostasis

Prostaglandin E2 (PGE2) plays a critical role in maintaining gastrointestinal mucosal integrity through cytoprotective mechanisms, primarily by inhibiting apoptosis in gastric epithelial cells via activation of EP3 receptors, which elevates intracellular cyclic AMP levels and suppresses pro-apoptotic signaling. This protection extends to enhancing mucus and bicarbonate secretion, thereby reinforcing the gastric mucosal barrier against acid and irritants, as evidenced by PGE2's ability to increase gastric potential difference by approximately 10 mV and mucus output by 50% in human studies. Endogenous PGE2, predominantly synthesized via cyclooxygenase-1 (COX-1), mediates adaptive cytoprotection in response to mild irritants, preventing severe damage through EP1 receptor signaling that limits acid secretion and promotes epithelial restitution. In the intestinal epithelium, PGE2 facilitates repair following injury by inducing an adaptive cellular response, including proliferation of stem cells and modulation of barrier function, though excessive levels can disrupt homeostasis by promoting inflammation via effects on mononuclear phagocytes and microbiota. In , PGE2 exerts dual effects on remodeling by stimulating both osteoclast-mediated resorption and osteoblast-driven formation, thereby balancing bone mass under physiological conditions such as mechanical loading or hormonal . It activates EP4 receptors on osteoclasts to modulate their activity—enhancing differentiation indirectly through osteoblast-derived signals while inhibiting resorptive function in mature cells—thus preventing excessive bone loss during progression or unloading states. Sensory nerves detect PGE2 secreted by osteoblasts via EP4 signaling to fine-tune bone formation, integrating environmental cues like to maintain structural integrity, as demonstrated in models where hypothalamic perception of bone PGE2 levels adjusts remodeling in response to altered loading. Deficiency in EP1 receptors, for instance, leads to enhanced bone acquisition and in aging models, underscoring PGE2's context-dependent role in suppressing excessive formation to preserve . Overall, PGE2's anabolic and catabolic actions, mediated by EP subtype distribution on bone cells, position it as a key and effector in trauma response and steady-state turnover.

Pathological Roles and Disease Associations

Promotion of Chronic Inflammation

Prostaglandin E2 (PGE2) perpetuates chronic inflammation by engaging EP2 and EP4 receptors on immune cells, elevating cyclic AMP (cAMP) levels, and amplifying pro-inflammatory signaling cascades such as NF-κB activation. This receptor-mediated action enhances cytokine receptor expression on T cells, including IL-23R on Th17 precursors and IL-12Rβ2 on Th1 cells, thereby sensitizing these populations to pathogenic stimuli like IL-23 and IFN-γ. In synergy with cytokines such as TNF-α and IL-23, PGE2 drives NF-κB-dependent transcription of inflammatory genes, including COX-2 itself, establishing a positive feedback loop that sustains elevated PGE2 production in inflamed tissues. A key mechanism involves the promotion of T helper 17 (Th17) cell differentiation and pathogenic conversion, where PGE2 via EP2/EP4 upregulates IL-23R and IL-1R on naive CD4+ T cells, cooperating with IL-1β and IL-23 to induce RORγt expression and robust IL-17A/IL-17F secretion. This enhances Th17 effector functions, including CCL20 production for self-recruitment via CCR6, and contributes to tissue damage in autoimmune conditions; for instance, in experimental autoimmune encephalomyelitis models of , PGE2-EP4 signaling exacerbates Th17-driven inflammation. Similarly, PGE2 boosts Th1 responses by increasing IFN-γ receptor density, amplifying IFN-γ-mediated activation and further cytokine storms. In antigen-presenting cells, PGE2 exacerbates chronicity by conditioning dendritic cells to produce excess IL-23 and express costimulatory molecules, priming Th17 expansion, while in macrophages, EP2 engagement triggers to elevate chemokine levels, recruiting monocytes that differentiate into pro-inflammatory subtypes. infiltration is also augmented via EP2- induction of , as observed in colorectal cancer-associated models where PGE2 drives persistent myeloid influx. These effects manifest in diseases like , where synovial PGE2 levels correlate with joint destruction, and COX-2-derived PGE2 inhibition in collagen-induced arthritis models reduces paw swelling by approximately 75% through diminished Th17/IL-17 activity. Beyond immune modulation, PGE2 fosters fibrotic remodeling in chronic settings, activating fibroblasts via EP2/EP4 to promote extracellular matrix deposition and α-smooth muscle actin expression, as evidenced in chronic pancreatitis where elevated PGE2 in pancreatic juice predicts fibrosis severity. In tumor microenvironments, PGE2-EP2 signaling coordinates chronic inflammation by suppressing anti-tumor immunity while enhancing angiogenesis and myeloid-derived suppressor cell recruitment, linking sustained PGE2 to increased tumor incidence in COX-2-overexpressing models. Genetic evidence supports these roles, with PTGER4 (EP4) polymorphisms associated with heightened risk in rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis cohorts. EP2/EP4 antagonists or knockouts consistently attenuate these pro-inflammatory pathways in preclinical studies, underscoring PGE2's causal contribution to chronicity over resolution in non-resolving inflammation.

Tumorigenesis and Immune Evasion in Cancer

Prostaglandin E2 (PGE2) contributes to tumorigenesis by enhancing tumor cell proliferation, inhibiting apoptosis, and promoting angiogenesis and metastasis across various cancers, including colorectal, breast, and lung malignancies. In colorectal cancer models, PGE2 signaling via EP2 and EP4 receptors activates pathways that upregulate matrix metalloproteinases and vascular endothelial growth factor, facilitating invasion and neovascularization. Studies in mouse xenografts demonstrate that elevated PGE2 levels, often driven by COX-2 overexpression, correlate with increased tumor burden and reduced programmed cell death through cAMP-dependent suppression of pro-apoptotic proteins like Bax. These effects are mediated by PGE2's interaction with EP receptor subtypes on tumor cells, where EP4 activation transduces signals via β-arrestin and Src kinases to boost cell migration and survival. In the (TME), PGE2 fosters immune evasion by dampening innate and adaptive antitumor responses. It inhibits natural killer (NK) cell cytotoxicity and production in through EP4-mediated suppression of perforin and interferon-γ release. PGE2 also impairs CD8+ T-cell expansion and effector differentiation; in tumor-infiltrating stem-like CD8+ T cells, PGE2 limits proliferative capacity via EP2/EP4 signaling, reducing TCF1+ progenitor pools and antitumor efficacy. phagocytosis of tumor cells is curtailed by PGE2, which downregulates signals, while function is disrupted, hindering and T-cell priming. PGE2 promotes immunosuppressive cell populations, including myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs). Tumor-derived PGE2 induces MDSC accumulation and activation, enhancing expression and production to deplete T-cell and suppress proliferation. In , COX-2-PGE2 signaling expands Tregs via upregulation, further blunting CD8+ T-cell responses. Dual blockade of and EP4 receptors restores immune cell bioenergetics and ribosome biogenesis, alleviating PGE2-induced metabolic suppression in the TME and enhancing antitumor immunity in preclinical models. These mechanisms underscore PGE2's role in creating an immunosuppressive niche that sustains tumor progression, with evidence from human tumor biopsies showing elevated PGE2 correlating with poor prognosis and reduced immune infiltration.

Contributions to Osteoarthritis and Tissue Degeneration

Prostaglandin E2 (PGE2) exacerbates (OA) pathogenesis through catabolic effects on articular and subchondral , primarily via activation of EP2 and EP4 receptors. In OA-affected joints, upregulated (COX-2) in chondrocytes and synovial cells elevates PGE2 levels, which stimulate matrix metalloproteinase-13 (MMP-13) expression in chondrocytes, accelerating collagen type II degradation and proteoglycan loss essential for integrity. This degradative cascade is evidenced by studies showing PGE2-mediated inhibition of proteoglycan synthesis alongside enhanced matrix breakdown in human OA explants. PGE2 further drives tissue degeneration by promoting aberrant subchondral . Acting on EP4 receptors in osteoclasts, PGE2 enhances osteoclastogenesis and , leading to microstructural changes like increased and vascular invasion that mechanically stress overlying . Experimental models, such as destabilization of the (DMM) in mice, demonstrate that PGE2 signaling heightens sensory innervation in subchondral bone from early OA stages, amplifying and potentially perpetuating inflammatory feedback loops that hasten degeneration. Inhibition of PGE2 production or signaling in these models attenuates erosion, subchondral sclerosis, and formation, underscoring its causal role. Beyond direct matrix effects, PGE2 fosters a pro-inflammatory milieu conducive to degeneration by inducing cytokines like interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) from synovial fibroblasts, which indirectly amplify . In damaged , PGE2 correlates with COX-2 expression, distinguishing pathological from healthy tissue, and contributes to and in joint capsules, further compromising load distribution. While low-dose PGE2 exhibits anabolic potential in acute models by suppressing certain degradative enzymes, chronic elevation in OA shifts toward net , as confirmed by reduced degeneration upon COX inhibitors that lower PGE2 without fully halting proteoglycan loss post-injury. These mechanisms highlight PGE2's integral role in the vicious cycle of inflammation-driven tissue breakdown in OA.

Therapeutic Applications

Labor Induction and Cervical Ripening

Prostaglandin E2, formulated as dinoprostone, serves as a pharmacological agent for cervical ripening and labor induction in term pregnancies with an unfavorable cervix, as indicated by a low Bishop score. It represents the only prostaglandin approved by the U.S. Food and Drug Administration for these obstetric applications, distinguishing it from analogs like misoprostol (prostaglandin E1). Dinoprostone is administered intravaginally, either as a controlled-release insert (10 mg, retained up to 12 hours) or gel (0.5 mg doses, repeatable every 6 hours up to 3 doses), with continuous electronic fetal monitoring required to assess uterine activity and fetal well-being. The mechanism involves binding to E-prostanoid (EP) receptors (primarily EP1-4) on cervical fibroblasts and smooth muscle cells, which promotes enzymatic degradation of cervical collagen via increased collagenase activity, enhances leading to and softening, and sensitizes the myometrium to endogenous oxytocin for contractile effects. This dual action facilitates effacement, dilation, and transition to active labor, typically within 6-12 hours of application, though varies by initial cervical status and parity. Clinical efficacy data from randomized trials and reviews indicate dinoprostone effectively elevates the Bishop score by at least 2 points in over 80% of cases and shortens the time to vaginal delivery compared to expectant management, often reducing the need for subsequent oxytocin augmentation in responsive patients. A 2024 meta-analysis of randomized controlled trials (n=1,858) comparing dinoprostone to vaginal misoprostol found no significant difference in vaginal delivery rates within 24 hours (relative risk [RR] 1.08, 95% CI 0.97-1.20) or overall (RR 1.05, 95% CI 0.95-1.16), though misoprostol required less oxytocin support (RR 0.83, 95% CI 0.71-0.97). Mechanical methods like Foley catheters may offer similar ripening success but prolong overall induction time relative to dinoprostone in low-risk cases. Safety profiles highlight reversible (contractions >5 in 10 minutes) in >2% of applications, exceeding rates (<1%), alongside fetal decelerations necessitating insert removal or tocolysis in rare instances. The same reported comparable hyperstimulation (RR 1.14, 95% CI 0.73-1.79), cesarean delivery (RR 0.95, 95% CI 0.74-1.21), and neonatal outcomes including NICU admissions (RR 0.76, 95% CI 0.42-1.37) and low Apgar scores (RR 1.18, 95% CI 0.38-3.65) between dinoprostone and . Gastrointestinal adverse effects remain low (<1% for inserts/gels), but contraindications include prior cesarean section due to rupture risk, active fetal distress, unexplained , or . Post-administration, failed induction warrants prompt discontinuation to mitigate prolonged exposure risks.

Termination of Intrauterine Pregnancy

Prostaglandin E2, formulated as dinoprostone (Prostin E2), serves as a pharmaceutical agent for terminating intrauterine pregnancies, primarily in the second trimester through induction of and cervical ripening. This application leverages PGE2's endogenous role in promoting myometrial contractility via EP receptor subtypes, particularly EP3 and EP4, which facilitate calcium influx and formation in uterine , culminating in fetal expulsion. Clinical protocols typically involve vaginal administration, with a standard dose of 20 mg inserted high into the every 4 to 6 hours, up to a maximum of 360 mg over 48 hours, under medical supervision in a setting to monitor for complications such as hyperstimulation. Efficacy data from controlled studies demonstrate high success rates for mid-trimester terminations; for instance, one series reported successful in 70 of 71 patients using vaginal PGE2 suppositories, with expulsion occurring within 24 to 48 hours in most cases. Dinoprostone is FDA-approved specifically for evacuating uterine contents in intrauterine fetal demise or for second-trimester induction, distinguishing it from first-trimester uses where it shows limited superiority over alternatives like PGF2α due to higher gastrointestinal side effects. In comparative trials, intravaginal PGE2 achieved complete rates comparable to (approximately 80-90% within 24 hours for second-trimester cases involving dead or living fetuses), though has largely supplanted it in practice for its lower cost, stability, and oral/vaginal versatility. Incomplete abortion occurs in a of cases, necessitating additional interventions such as or oxytocin augmentation, as the process mimics spontaneous but may not fully evacuate retained products. Safety profiles indicate vaginal PGE2 as reliable for managing missed abortions and intrauterine fetal death, with lower risks of systemic effects compared to intravenous routes, though monitoring for fever, , and uterine hypertonus remains essential. Historical clinical adoption dates to the 1970s, with early trials confirming its utility for therapeutic even in the first trimester, albeit with evolving preferences toward regimen optimizations for efficacy and tolerability.

Neonatal Patency of Ductus Arteriosus

In neonates with ductus-dependent congenital heart defects, such as those involving obstructive lesions of the right (e.g., or critical pulmonary ), systemic blood flow or pulmonary blood flow relies on patency of the (DA) until surgical intervention can be performed. Prostaglandin E2 (PGE2) infusion is administered therapeutically to maintain DA patency by inducing through activation of the EP4 receptor on ductal cells, which elevates intracellular cyclic AMP (cAMP) levels and promotes relaxation. This approach has been employed intravenously or orally, with PGE2 demonstrating efficacy comparable to PGE1 (alprostadil) in sustaining ductal opening and improving oxygenation in affected infants. Early clinical reports from the documented successful use of PGE2 in cyanotic neonates, where infusion prevented ductal closure and alleviated ; for instance, in four cases of ductal-dependent cyanotic heart disease, PGE2 maintained patency without immediate surgical need. Oral PGE2 has also proven responsive in ductus-dependent , with withdrawal leading to desaturation (e.g., mean arterial dropping from 75% to 57%), indicating sustained ductal sensitivity even after prolonged administration. These applications underscore PGE2's role in bridging the gap to definitive repair, though monitoring for side effects such as apnea, , or seizures is essential, as with other E-type prostaglandins. While PGE1 remains the standard agent for DA patency in modern neonatal intensive care due to its stability and licensing, PGE2 shares the same mechanistic pathway and has been utilized in similar low-dose intravenous (e.g., substituting for oral ) or oral regimens to support ductal-dependent lesions. Postnatal PGE2 levels naturally decline, facilitating physiological DA closure in healthy term infants, but exogenous administration counters this in therapeutic contexts by mimicking fetal conditions of high exposure. Outcomes depend on timely initiation before ductal constriction, with confirming patency response.

Emerging Targets in Regeneration and Pain Management

Prostaglandin E2 (PGE2) signaling via and EP4 receptors promotes (MuSC) activation and proliferation, enhancing regeneration after injury. In aged mice, a single brief exposure to PGE2 restores youthful MuSC function by reversing epigenetic and transcriptomic dysfunctions, resulting in up to 30% greater muscle force generation post-injury compared to untreated controls, as shown in multiomic analyses of over 10,000 genes and accessibility profiles.00192-4) This effect stems from PGE2-mediated upregulation of revival stem cell lineages and YAP/TEAD pathways, which drive myogenic differentiation without exacerbating inflammation. Such findings position EP2/EP4 agonists as candidates for treating , though long-term human trials remain absent as of 2025. In , PGE2 acts through EP4 on resident macrophages to sustain the niche, accelerating repair following dextran sulfate sodium-induced damage; EP4-deficient models exhibit delayed crypt regeneration and heightened susceptibility to . regeneration benefits from PGE2-EP4 signaling in sensory nerves, which boosts activity and mineralization in response to mechanical loading, with EP4 reducing mass accrual by 20-25% in murine models. Corneal epithelial repair likewise involves dose-dependent PGE2 effects, where moderate levels (10-100 nM) via EP2/EP4 enhance release and migration, contrasting high doses that impair healing through excessive . For pain management, selective EP2 antagonism in Schwann cells emerges as a targeted approach to mitigate neuropathic , blocking PGE2-induced mechanical in models without suppressing acute inflammation or , unlike broad COX inhibitors. This specificity arises from EP2's role in amplifying sensitization downstream of PGE2, independent of leukocyte recruitment. In , PGE2 contributes to chronic joint pain via EP4-mediated excitation and synovial inflammation; novel EP4 antagonists, such as CJ-42794 derivatives, reduce pain scores by 40-50% in preclinical assays while preserving bone homeostasis. EP1 receptor blockade similarly attenuates inflammatory by inhibiting PGE2-driven activation in dorsal root ganglia, offering potential over non-selective NSAIDs by minimizing gastrointestinal risks. These receptor-specific modulators highlight PGE2 pathways as tunable targets, with phase II trials for EP4 inhibitors in postoperative pain underway as of 2025, though efficacy in non- models requires validation.

Pharmacological Profile

Routes of Administration

Prostaglandin E2 (PGE2), marketed as dinoprostone, is most commonly administered intravaginally for therapeutic purposes such as cervical ripening and . Vaginal suppositories containing 20 mg of dinoprostone are inserted into the posterior fornix of the , where they dissolve to stimulate myometrial contractions mimicking natural labor. Endocervical gel formulations deliver 0.5 mg of PGE2 directly into the via a , promoting local effects with minimal systemic absorption. Controlled-release vaginal inserts provide 10 mg of dinoprostone, releasing approximately 0.3 mg per hour over 12 hours to sustain cervical softening and dilation while allowing for timely removal if needed. Oral administration of PGE2 occurs via 0.5 mg tablets swallowed with water, primarily for inducing labor in settings where vaginal routes are contraindicated. Dosing starts low and titrates based on uterine response to avoid hyperstimulation, though this route carries a higher of gastrointestinal side effects compared to local applications. Less conventional routes, including intracervical injection or extra-amniotic infusion, have been investigated for cervical ripening but are rarely used in standard due to procedural complexity and potential for uneven absorption. Intravenous PGE2 has been explored experimentally for rapid uterine stimulation but is avoided routinely owing to pronounced systemic effects like and fever.

Pharmacokinetics and Metabolism

Prostaglandin E2 (PGE2), whether endogenous or exogenously administered, exhibits rapid inactivation , with a plasma typically under 1 minute due to efficient enzymatic degradation that limits systemic exposure and promotes localized effects. The primary involves oxidation of the 15α-hydroxyl group by 15-hydroxyprostaglandin (15-PGDH), yielding the biologically inactive 13,14-dihydro-15-keto-PGE2; this is followed by Δ13 reduction and further transformations into metabolites such as 13,14-dihydro-15-keto-PGA2. Metabolism occurs predominantly in pulmonary, hepatic, renal, and splenic tissues, with approximately 95% of circulating PGE2 cleared during the first pass through the lungs. For therapeutic applications, such as dinoprostone (synthetic PGE2) used in via vaginal administration, absorption is route-dependent and controlled to achieve local cervical effects while minimizing plasma peaks; vaginal inserts release approximately 0.3 mg per hour over 12 hours, with levels peaking around 40 minutes post-insertion. Distribution is widespread in maternal tissues, but the short of 2.5–5 minutes prevents significant accumulation, and elimination occurs mainly via renal excretion of metabolites, with minor fecal contributions. These pharmacokinetic properties underscore PGE2's design for , where therapeutic formulations exploit local delivery to bypass rapid circulatory inactivation.

Adverse Effects and Toxicity

The primary adverse effects of exogenously administered prostaglandin E2 (PGE2), most commonly as dinoprostone in vaginal , gel, or insert formulations for or cervical ripening, involve gastrointestinal disturbances and uterine hyperactivity. occurs in approximately 33% of patients, in 66%, and in 40% with suppository use, often necessitating antiemetics or antidiarrheals for management. Fever affects about 50% of recipients, alongside less frequent symptoms such as (10%) and or (10%). Uterine hyperstimulation, defined as excessive or prolonged contractions, arises in more than 2% of cases (versus <1% with ), potentially accompanied by fetal heart rate abnormalities or distress in over 2% of treated pregnancies (versus 1% ). , vaginal warmth, and increased contraction frequency are also reported, with fetal noted in some instances. Serious adverse effects, though rarer, include reactions (e.g., ), (particularly in patients with history), , and amniotic or . or hemorrhage, fetal distress leading to or neonatal death, and post-partum have been documented, with the latter occurring in fewer than 1 per 1,000 labors. Gastrointestinal effects predominate due to PGE2's stimulation of , while maternal cardiovascular strain may exacerbate risks in those with pre-existing conditions. Toxicity from overdose primarily manifests as sustained uterine hypertonus or hypercontractility, potentially progressing to fetal compromise or maternal hemorrhage if unaddressed. Overdose is managed by immediate drug discontinuation, maternal repositioning, oxygen supplementation, and agents like to relax uterine tone; no specific exists. Systemic toxicity is minimized by localized vaginal administration, but high-dose oral PGE2 regimens have historically induced and severe gastrointestinal in up to 92% of recipients in clinical settings. Monitoring for fetal and contraction patterns is essential during use to mitigate these risks.

Contraindications and Drug Interactions

Prostaglandin E2 (PGE2), administered therapeutically as dinoprostone, is contraindicated in patients with known to prostaglandins or any components of the formulation, due to risk of severe allergic reactions. It should not be used in scenarios where oxytocic agents are inappropriate, including clinical suspicion or evidence of fetal distress without imminent delivery, unexplained during , or conditions necessitating avoidance of prolonged , such as previa or active cardiac . Additional contraindications include grand multiparity (six or more previous term pregnancies), history of difficult or traumatic deliveries, and non-vertex fetal presentation, as these increase risks of or hyperstimulation. In patients with (including childhood history) or , PGE2 may provoke and narrowing of pulmonary vasculature, exacerbating respiratory compromise. Caution or avoidance is advised in due to potential elevation of and pupillary constriction from prostaglandin effects. Dinoprostone augments the activity of other oxytocic agents, including oxytocin, ergonovine, methylergonovine, , and , potentially leading to , fetal distress, or rupture; concomitant use is generally not recommended without close monitoring. Prior removal of any dinoprostone insert or is essential before initiating oxytocin, as residual effects can intensify contractions. Interactions with may enhance effects but require careful dosing to avoid excessive stimulation. No significant pharmacokinetic interactions with beta-adrenergic agents have been widely reported, though PGE2 may modulate cyclic AMP pathways in certain tissues. Overall, six major drug interactions are documented, emphasizing the need for sequential rather than combined oxytocic therapy.

Historical Development

Discovery and Initial Characterization

Prostaglandins were first detected in by Swedish physiologist Ulf S. von Euler, who identified bioactive factors in human seminal fluid that elicited contraction or relaxation in isolated preparations, such as jejunum strips. Independently, British physiologist Maurice W. Goldblatt reported comparable effects from in the same year. Von Euler proposed the name "prostaglandin" for these substances, presuming an origin in the prostate gland, though subsequent work showed production across multiple tissues including lungs, iris, , and . Initial biochemical characterization in the 1930s and 1940s established prostaglandins as ether-soluble, acidic of low molecular weight (around 300-500 Da), stable to alkali but labile to acid, with potent vasodepressor and hypotensive activities . Bioassays on ileum and rat colon quantified their potency, distinguishing them from known hormones like or . Efforts to isolate pure forms stalled due to low yields and instability, but techniques revealed multiple active components separable by distribution between organic solvents and phosphate buffers. Prostaglandin E2 (PGE2) emerged from these efforts through purification from sheep by Sune Bergström's group at the in the mid-1950s. By 1957, they had isolated two major acidic prostaglandins via countercurrent distribution and silicic acid chromatography, designating the more polar one as PGE2 based on its UV absorption at 278 nm (due to the α,β-unsaturated ) and slower migration on reversed-phase partitions compared to PGE1. Full structural identification of PGE2 as (5Z,11α,13E,15S)-11,15-dihydroxy-9-oxoprost-5,13-dienoic acid was achieved in 1962 using , NMR, and degradation studies, confirming its derivation from via oxidative cyclization. This work laid the foundation for biosynthetic pathway elucidation, with enzymatic conversion from demonstrated by 1964.

Key Milestones in Synthesis and Receptor Identification

The structural elucidation of prostaglandin E2 (PGE2) in the early 1960s by paved the way for synthetic efforts, as natural extraction from biological sources yielded limited quantities. A landmark milestone was the first of PGE2, achieved by Elias J. Corey and coworkers in 1969 through a multi-step route involving stereocontrolled construction of the ring and side chains, published the following year; this approach not only confirmed the structure but facilitated production of analogs for therapeutic evaluation. Corey's methodology, emphasizing , represented a breakthrough in complex synthesis and contributed to his 1990 . Pharmacological studies in the and provided evidence for multiple PGE2 receptor subtypes based on differential tissue responses and antagonist profiles, suggesting at least four distinct classes (later termed EP1–EP4). Molecular identification accelerated in the early with cDNA : the EP1 receptor was cloned from and tissues in 1993, revealing a Gq-coupled G-protein-coupled receptor (GPCR) . This was followed by of EP2 (Gs-coupled) and EP4 (also Gs-coupled) in 1994, initially with EP4 misidentified as a second EP2 variant before subtype distinction via sequence and functional assays. The EP3 receptor (Gi/o-coupled), featuring splice variants, was cloned concurrently around 1993, completing the identification of the four EP subtypes and enabling targeted ligand development. These clonings confirmed PGE2's diverse signaling via cAMP modulation and calcium mobilization, underpinning subtype-specific roles in and .

Recent Research Advances

Advances in Muscle Stem Cell Regeneration

Prostaglandin E2 (PGE2) serves as a critical inflammatory mediator that enhances the regenerative capacity of muscle (MuSCs), also known as cells, during repair. In acute models, PGE2 signaling promotes MuSC proliferation, migration, and differentiation, thereby augmenting muscle regeneration and functional recovery; of PGE2 production impairs these processes, leading to reduced muscle strength. This effect occurs primarily through and EP4 receptors on MuSCs, which activate cyclic AMP pathways to inhibit myogenic differentiation while favoring expansion of the stem cell pool. Recent advances have focused on leveraging PGE2 to counteract age-related MuSC dysfunction, where declining PGE2 levels contribute to impaired regeneration and . A 2025 multiomic study demonstrated that short-term exposure to PGE2 reverses transcriptional and epigenetic signatures of aging in MuSCs, restoring their long-term regenerative potential upon transplantation into aged models; treated cells showed enhanced engraftment, proliferation, and contribution to myofiber formation compared to untreated aged controls.00192-4) This rejuvenation modulates key transcription factors, such as those regulating mitochondrial function and inflammatory responses, leading to improved muscle strength and repair efficiency when combined with exercise. In muscle models of aging-aggravated atrophy, PGE2 administration ameliorated mitochondrial dysfunction and in MuSCs, promoting satellite cell activation and reducing ; treated aged mice exhibited preserved muscle mass and force generation versus vehicle controls. These findings suggest transient PGE2 supplementation as a therapeutic to boost MuSC function without chronic inflammation risks, though human translation requires validation of dosing and receptor specificity to avoid off-target effects in fibrotic or pathological contexts. Ongoing research explores PGE2 analogs or enzyme modulators (e.g., targeting 15-PGDH) to sustain elevated PGE2 levels selectively in aged MuSCs, potentially integrating with therapies for enhanced repair.

Novel Inhibitors for Cancer and Inflammatory Diseases

Research into novel inhibitors of prostaglandin E2 (PGE2) has focused on targeting its synthesis via microsomal PGE2 synthase-1 (mPGES-1) or its signaling through and EP4 receptors, aiming to mitigate PGE2's roles in promoting chronic , tumor progression, immune evasion, and metastasis without the cardiovascular risks associated with upstream (COX) inhibitors. mPGES-1 inhibition selectively reduces PGE2 production in inflammatory contexts, preserving other prostaglandins that maintain gastrointestinal and renal . Recent structural and efforts have yielded potent mPGES-1 inhibitors, such as novel derivatives exhibiting values in the low nanomolar range and demonstrating efficacy in preclinical models of and . For inflammatory diseases, mPGES-1 inhibitors like repurposed from have shown promise in reducing PGE2-driven release and joint inflammation in models, with ongoing efforts to optimize selectivity and for clinical translation. In cancer, PGE2-EP2/EP4 signaling fosters an immunosuppressive by impairing T-cell and NK-cell function while enhancing myeloid-derived suppressor cell activity; dual antagonists address redundancy between these receptors, outperforming single-target agents in preclinical tumor models. For instance, TPST-1495, a dual EP2/EP4 antagonist, synergizes with checkpoint inhibitors to boost CD8+ T-cell infiltration and tumor regression in syngeneic mouse models of colorectal and . EP4-selective antagonists, such as vorbipiprant, have advanced to combination trials with anti-PD-1 therapies (e.g., balstilimab) in solid tumors, where they reverse PGE2-mediated TIL dysfunction by restoring IL-2 signaling and effector cytokine production, with phase I data reporting improved response rates in PGE2-high subsets as of 2025. Similarly, OCT-598, a potent dual EP2/EP4 blocker, inhibits PGE2-induced angiogenesis and metastasis in colorectal cancer xenografts, highlighting its potential to disrupt EP-mediated cAMP elevation and β-catenin activation. Other candidates like ACT-1002-4391 exhibit balanced EP2/EP4 affinity (Ki <1 nM) and oral bioavailability, supporting evaluation in inflammation-associated cancers. These developments underscore a shift toward receptor-specific or downstream inhibition to enhance efficacy while minimizing off-target effects, though long-term safety in human trials remains under investigation.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC3593876/
  2. https://pubmed.ncbi.nlm.nih.gov/16336776/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC166355/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC3081099/
  5. https://www.tandfonline.com/doi/full/10.1080/23328940.2024.2401674
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC2014644/
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC8641993/
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC3568185/
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC8419039/
  10. https://article.imrpress.com/bri/Landmark/articles/pdf/Landmark1383.pdf
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC4759316/
  12. https://pubmed.ncbi.nlm.nih.gov/16540375/
  13. https://pubmed.ncbi.nlm.nih.gov/21232167/
  14. https://pubmed.ncbi.nlm.nih.gov/10206978/
  15. https://pubmed.ncbi.nlm.nih.gov/12432931/
  16. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/prostaglandin-e-synthase
  17. https://pubchem.ncbi.nlm.nih.gov/compound/Prostaglandin-E2
  18. https://www.researchgate.net/publication/23808606_Stability_of_Prostaglandin_E_2_PGE_2_Embedded_in_Poly-d_l-Lactide-co-Glycolide_Microspheres_A_pre-Conditioning_Approach_for_Tissue_Engineering_Applications
  19. https://reactome.org/content/detail/R-HSA-2161659
  20. https://www.sciencedirect.com/science/article/abs/pii/S0022354915389875
  21. https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8461799.htm
  22. https://www.sigmaaldrich.com/deepweb/assets/sigmaaldrich/product/documents/407/849/p0409pis.pdf
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC7988772/
  24. https://www.sciencedirect.com/science/article/pii/S1359644616302902
  25. https://link.springer.com/article/10.1007/s10555-011-9317-9
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC7907432/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC3236828/
  28. https://journals.physiology.org/doi/pdf/10.1152/ajpregu.00185.2020
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC5181317/
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC199422/
  31. https://pubmed.ncbi.nlm.nih.gov/6340897/
  32. https://www.sciencedirect.com/science/article/abs/pii/S0143400420304653
  33. https://www.ncbi.nlm.nih.gov/books/NBK545279/
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC7138281/
  35. https://pubmed.ncbi.nlm.nih.gov/28585102/
  36. https://pubmed.ncbi.nlm.nih.gov/2648830/
  37. https://www.sciencedirect.com/science/article/pii/002822439190291R
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC6205862/
  39. https://academic.oup.com/humupd/article/21/5/652/565672
  40. https://pubmed.ncbi.nlm.nih.gov/29716588/
  41. https://www.mdpi.com/2673-396X/1/1/3
  42. https://www.ahajournals.org/doi/10.1161/hypertensionaha.107.088948
  43. https://academic.oup.com/cardiovascres/article/83/1/148/312262
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC3578476/
  45. https://journals.physiology.org/doi/abs/10.1152/ajpheart.00538.2019
  46. https://pubmed.ncbi.nlm.nih.gov/6442643/
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC3894486/
  48. https://pubmed.ncbi.nlm.nih.gov/10654821/
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC2653111/
  50. https://bmcnephrol.biomedcentral.com/articles/10.1186/1471-2369-11-28
  51. https://www.ahajournals.org/doi/10.1161/JAHA.123.032835
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC8816406/
  53. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.875425/full
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC6121522/
  55. https://www.nature.com/articles/s41598-024-67793-1
  56. https://www.jneurosci.org/content/24/3/642
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC2846228/
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC3249979/
  59. https://pubmed.ncbi.nlm.nih.gov/25917098/
  60. https://pubmed.ncbi.nlm.nih.gov/23024463/
  61. https://ashpublications.org/blood/article/119/10/2358/29526/Prostaglandin-E2-restrains-macrophage-maturation
  62. https://ashpublications.org/blood/article/113/11/2451/109984/Prostaglandin-E2-enhances-T-cell-proliferation-by
  63. https://www.sciencedirect.com/science/article/abs/pii/S0024320524003412
  64. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.01441/full
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC3389798/
  66. https://www.nature.com/articles/s41586-024-07254-x
  67. https://pubmed.ncbi.nlm.nih.gov/28954232/
  68. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1099811/full
  69. https://pubmed.ncbi.nlm.nih.gov/30926983/
  70. https://pubmed.ncbi.nlm.nih.gov/12556459/
  71. https://www.tandfonline.com/doi/abs/10.3109/00365528109182025
  72. https://www.kjim.org/journal/view.php?number=15530
  73. https://www.sciencedirect.com/science/article/abs/pii/S0022356524296464
  74. https://www.embopress.org/doi/10.15252/embj.201694660
  75. https://pmc.ncbi.nlm.nih.gov/articles/PMC7880593/
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC2862787/
  77. https://www.nature.com/articles/s41413-022-00201-4
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC8904489/
  79. https://www.nature.com/articles/s41467-018-08097-7
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC6331599/
  81. https://pmc.ncbi.nlm.nih.gov/articles/PMC4437532/
  82. https://pmc.ncbi.nlm.nih.gov/articles/PMC6014392/
  83. https://pmc.ncbi.nlm.nih.gov/articles/PMC6329627/
  84. https://rupress.org/jem/article/206/3/535/40458/Prostaglandin-E2-regulates-Th17-cell
  85. https://journals.lww.com/10.14309/ctg.0000000000000897
  86. https://inflammregen.biomedcentral.com/articles/10.1186/s41232-017-0036-7
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC7760298/
  88. https://pmc.ncbi.nlm.nih.gov/articles/PMC9911818/
  89. https://pmc.ncbi.nlm.nih.gov/articles/PMC8930508/
  90. https://aacrjournals.org/cancerpreventionresearch/article/15/5/285/694474/The-COX-2-PGE2-Pathway-Promotes-Tumor-Evasion-in
  91. https://aacrjournals.org/clincancerres/article/20/15/4096/206190/Inhibition-of-Tumor-Derived-Prostaglandin-E2
  92. https://www.nature.com/articles/s41467-024-53706-3
  93. https://pmc.ncbi.nlm.nih.gov/articles/PMC12317822/
  94. https://pmc.ncbi.nlm.nih.gov/articles/PMC2659545/
  95. https://pmc.ncbi.nlm.nih.gov/articles/PMC9454853/
  96. https://www.mdpi.com/2073-4409/11/17/2760
  97. https://pubmed.ncbi.nlm.nih.gov/38262526/
  98. https://pmc.ncbi.nlm.nih.gov/articles/PMC2206385/
  99. https://pmc.ncbi.nlm.nih.gov/articles/PMC2246251/
  100. https://www.ajog.org/article/S0002-9378(23)00081-9/fulltext
  101. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1459793/full
  102. https://labeling.pfizer.com/showlabeling.aspx?id=603
  103. https://go.drugbank.com/drugs/DB00917
  104. https://pubmed.ncbi.nlm.nih.gov/1155530/
  105. https://www.nejm.org/doi/full/10.1056/NEJM199408043310502
  106. https://www.ajog.org/article/0002-9378%2877%2990032-1/fulltext
  107. https://pubmed.ncbi.nlm.nih.gov/2563705/
  108. https://www.bmj.com/content/bmj/3/5716/198.full.pdf
  109. https://pubmed.ncbi.nlm.nih.gov/56243/
  110. https://www.ncbi.nlm.nih.gov/books/NBK500295/
  111. https://pubmed.ncbi.nlm.nih.gov/3474149/
  112. https://pubmed.ncbi.nlm.nih.gov/7460252/
  113. https://www.ahajournals.org/doi/10.1161/01.cir.53.4.728
  114. https://pubmed.ncbi.nlm.nih.gov/3865636/
  115. https://pmc.ncbi.nlm.nih.gov/articles/PMC2836805/
  116. https://publications.aap.org/pediatrics/article/146/5/e20201209/75323/Patent-Ductus-Arteriosus-of-the-Preterm-Infant
  117. https://www.nature.com/articles/s41392-025-02248-1
  118. https://pubmed.ncbi.nlm.nih.gov/33558271/
  119. https://www.sciencedirect.com/science/article/pii/S2589004223026421
  120. https://www.nature.com/articles/s41467-025-63782-8
  121. https://www.sciencedirect.com/science/article/abs/pii/S0045206825008855
  122. https://www.jci.org/articles/view/6749
  123. https://www.sciencedirect.com/science/article/abs/pii/S1521661624000159
  124. https://www.mayoclinic.org/drugs-supplements/dinoprostone-vaginal-route/description/drg-20063461
  125. https://www.drugs.com/dosage/dinoprostone-topical.html
  126. https://labeling.pfizer.com/ShowLabeling.aspx?id=13263
  127. https://pmc.ncbi.nlm.nih.gov/articles/PMC10771813/
  128. https://www.nature.com/articles/s41467-023-36463-7
  129. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020411Orig1s031lbl.pdf
  130. https://labeling.pfizer.com/ShowLabeling.aspx?id=12160
  131. https://www.sciencedirect.com/science/article/abs/pii/S1521693403000439
  132. https://www.drugs.com/mtm/prostin-e2.html
  133. https://pubmed.ncbi.nlm.nih.gov/7942940/
  134. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017810s019lbl.pdf
  135. https://www.drugs.com/pro/dinoprostone.html
  136. https://www.glowm.com/resources/glowm/cd/pages/drugs/d044.html
  137. https://www.drugs.com/drug-interactions/dinoprostone-topical%2Cprostin-e2.html
  138. https://pubmed.ncbi.nlm.nih.gov/6090568/
  139. https://www.drugs.com/drug-interactions/dinoprostone-topical.html
  140. https://www.acs.org/molecule-of-the-week/archive/p/prostaglandin-e2.html
  141. https://pmc.ncbi.nlm.nih.gov/articles/PMC6451071/
  142. https://www.nobelprize.org/prizes/medicine/1982/press-release/
  143. https://pubmed.ncbi.nlm.nih.gov/6792574/
  144. https://www.pnas.org/doi/10.1073/pnas.1705420114
  145. https://med.stanford.edu/news/all-news/2025/06/muscle-aging.html
  146. https://www.technologynetworks.com/cell-science/news/pge2-treatment-restores-muscle-stem-cell-function-in-aged-mice-401014
  147. https://www.researchgate.net/publication/392473906_PGE2_Ameliorates_Aging-Aggravated_Rotator_Cuff_Muscle_Atrophy
  148. https://www.sciencedirect.com/science/article/abs/pii/S1934590925001924
  149. https://med.stanford.edu/blau-lab/research.html
  150. https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2025.1658062/full
  151. https://www.tandfonline.com/doi/full/10.2147/JIR.S278514
  152. https://www.sciencedirect.com/science/article/abs/pii/S1093326325000221
  153. https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c01883
  154. https://pmc.ncbi.nlm.nih.gov/articles/PMC10408683/
  155. https://jitc.bmj.com/content/9/Suppl_2/A891
  156. https://aacrjournals.org/clincancerres/article-pdf/31/4/649/3541467/ccr-24-2611.pdf
  157. https://www.nature.com/articles/s41586-024-07352-w
  158. https://aacrjournals.org/cancerres/article/85/8_Supplement_1/3069/757495/Abstract-3069-Inhibition-of-PGE2-signaling-by-an
  159. https://aacrjournals.org/cancerres/article/83/7_Supplement/1809/722425/Abstract-1809-ACT-1002-4391-A-novel-potent
  160. https://pmc.ncbi.nlm.nih.gov/articles/PMC10258902/
  161. https://www.biorxiv.org/content/10.1101/2024.10.10.617574v1.full-text
Add your contribution
Related Hubs
User Avatar
No comments yet.